Edition:
United Kingdom

SAGE Therapeutics Inc (SAGE.O)

SAGE.O on Consolidated Issue listed on NASDAQ Global Market

123.83USD
18 Oct 2018
Change (% chg)

$2.39 (+1.97%)
Prev Close
$121.44
Open
$121.24
Day's High
$124.54
Day's Low
$120.62
Volume
388,014
Avg. Vol
467,009
52-wk High
$195.97
52-wk Low
$59.57

Chart for

About

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and... (more)

Overall

Beta: --
Market Cap(Mil.): $2,399.97
Shares Outstanding(Mil.): 37.44
Dividend: --
Yield (%): --

Financials

  SAGE.O Industry Sector
P/E (TTM): -- 85.83 33.69
EPS (TTM): -6.05 -- --
ROI: -85.13 0.58 14.30
ROE: -85.28 1.62 16.03

BRIEF-Sage Therapeutics Reports Quarterly Loss Per Share Of $1.68

* SAGE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON PIPELINE AND PROGRESS TOWARD LAUNCH READINESS

03 May 2018

BRIEF-Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression

* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION

23 Apr 2018

Earnings vs. Estimates